Rizatriptan wafer-sublingual vs. placebo at the onset of acute migraine

Cephalalgia

Volumn 20, Issue 6, 2000, Pages 585-588

  Klapper, J A ^a   O'Connor, S ^a  

^a Colorado Neurology and Headache Center ^*  (United States)

Author keywords

Migraine; Placebo response; Rizatriptan wafer; Sublingual

Indexed keywords

PLACEBO; RIZATRIPTAN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MIGRAINE; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME;

EID: 0034454818     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2000.00079.x     Document Type: Article

References (5)

1. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders?
2. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies
3. Efficacy and safety of rizatriptan wafer for acute treatment of migraine
4. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain